The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis
Citations Over TimeTop 10% of 2012 papers
Abstract
Amyotrophic lateral sclerosis (ALS) is an incurable and fatal neurodegenerative disease characterized by the loss of motor neurons. Despite substantial research, the causes of ALS remain unclear. Glycoprotein nonmetastatic melanoma protein B (GPNMB) was identified as an ALS-related factor using DNA microarray analysis with mutant superoxide dismutase (SOD1(G93A)) mice. GPNMB was greatly induced in the spinal cords of ALS patients and a mouse model as the disease progressed. It was especially expressed in motor neurons and astrocytes. In an NSC34 cell line, glycosylation of GPNMB was inhibited by interaction with SOD1(G93A), increasing motor neuron vulnerability, whereas extracellular fragments of GPNMB secreted from activated astrocytes attenuated the neurotoxicity of SOD1(G93A) in neural cells. Furthermore, GPNMB expression was substantial in the sera of sporadic ALS patients than that of other diseased patients. This study suggests that GPNMB can be a target for therapeutic intervention for suppressing motor neuron degeneration in ALS.
Related Papers
- → Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury(1996)1,270 cited
- → A Drosophila Model for Amyotrophic Lateral Sclerosis Reveals Motor Neuron Damage by Human SOD1(2008)158 cited
- → Restricted expression of mutant SOD1 in spinal motor neurons and interneurons induces motor neuron pathology(2007)101 cited
- → Amyotrophic lateral sclerosis: all roads lead to Rome(2006)74 cited
- Progress in the relationship between mutant SOD1 and amyotrophic lateral sclerosis.(2009)